Lecap Asset Management Ltd. Sells 36,278 Shares of Doximity, Inc. $DOCS

Lecap Asset Management Ltd. lessened its holdings in shares of Doximity, Inc. (NASDAQ:DOCS) by 85.3% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 6,228 shares of the company’s stock after selling 36,278 shares during the quarter. Lecap Asset Management Ltd.’s holdings in Doximity were worth $382,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. SG Americas Securities LLC acquired a new position in shares of Doximity during the 1st quarter worth $65,702,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Doximity by 130.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,966,801 shares of the company’s stock worth $114,133,000 after purchasing an additional 1,113,076 shares in the last quarter. Vanguard Group Inc. increased its position in Doximity by 8.8% during the first quarter. Vanguard Group Inc. now owns 12,194,492 shares of the company’s stock worth $707,646,000 after buying an additional 990,923 shares during the last quarter. Invesco Ltd. raised its holdings in Doximity by 54.8% during the first quarter. Invesco Ltd. now owns 1,969,326 shares of the company’s stock valued at $114,280,000 after buying an additional 696,923 shares in the last quarter. Finally, Nuveen LLC bought a new position in Doximity during the first quarter valued at about $34,056,000. 87.19% of the stock is currently owned by institutional investors and hedge funds.

Doximity Price Performance

Shares of Doximity stock opened at $73.25 on Friday. The company has a market cap of $13.72 billion, a PE ratio of 73.25, a price-to-earnings-growth ratio of 4.10 and a beta of 1.37. The firm has a fifty day moving average price of $67.25 and a two-hundred day moving average price of $60.72. Doximity, Inc. has a fifty-two week low of $40.87 and a fifty-two week high of $85.21.

Doximity (NASDAQ:DOCS) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.36 EPS for the quarter, beating analysts’ consensus estimates of $0.31 by $0.05. Doximity had a net margin of 36.60% and a return on equity of 21.75%. During the same quarter last year, the company earned $0.28 earnings per share. Doximity’s revenue for the quarter was up 15.2% compared to the same quarter last year. Doximity has set its FY 2026 guidance at EPS. Q2 2026 guidance at EPS. Analysts expect that Doximity, Inc. will post 0.99 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Regina M. Benjamin sold 5,000 shares of the company’s stock in a transaction on Friday, September 12th. The stock was sold at an average price of $70.50, for a total value of $352,500.00. Following the completion of the transaction, the director directly owned 19,839 shares in the company, valued at approximately $1,398,649.50. This represents a 20.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Kira Scherer Wampler sold 2,000 shares of Doximity stock in a transaction on Friday, August 1st. The stock was sold at an average price of $57.09, for a total transaction of $114,180.00. Following the sale, the director owned 16,618 shares in the company, valued at $948,721.62. This represents a 10.74% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 37,000 shares of company stock worth $2,581,880. 31.30% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on DOCS. Wells Fargo & Company increased their price objective on Doximity from $55.00 to $62.00 and gave the company an “equal weight” rating in a report on Monday, August 4th. Zacks Research downgraded Doximity from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 20th. Canaccord Genuity Group boosted their price objective on shares of Doximity from $59.00 to $67.00 and gave the stock a “hold” rating in a research note on Thursday, September 18th. Robert W. Baird upped their price objective on shares of Doximity from $75.00 to $80.00 and gave the stock an “outperform” rating in a report on Thursday, September 11th. Finally, Evercore ISI upgraded shares of Doximity from an “in-line” rating to an “outperform” rating and lifted their target price for the stock from $50.00 to $70.00 in a report on Wednesday, July 9th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $68.16.

About Doximity

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.